
Tavira Therapeutics Secures VLAIO Funding to Advance AAV Gene Therapy Innovations
Feb 4
1 min read
Leuven, Belgium — Feb 5, 2025 — Tavira Therapeutics, a spin-out biotech company from KU Leuven specializing in gene therapy delivery, has been awarded a €344K research grant by VLAIO (Flemish Agency for Innovation and Entrepreneurship) to accelerate the development of its groundbreaking AAV capsid platform technology.
With the growing demand for capsids capable of reaching the central nervous system (CNS) via intravenous administration, Tavira is leveraging its AAV conjugation technology to shuttle AAV vectors efficiently across the blood-brain-barrier. The funding will support Tavira Therapeutics in advancing its modular AAV delivery platform and drive the development of Tavira’s therapeutic pipeline.
“By addressing the challenges of targeted delivery to the CNS, we are unlocking new possibilities for the development of transformative therapies that have the potential to profoundly improve the lives of patients with neurological disorders. I am incredibly excited about the journey ahead as we push the boundaries of AAV gene therapy to unlock its full potential.” said Prof. Dr. Els Henckaerts, Co-Founder and interim CSO of Tavira Therapeutics.
About Tavira Therapeutics
Founded as a spin-out biotech company from KU Leuven together with General Inception in 2023, Tavira Therapeutics has developed an innovative process that equips AAV vectors with molecules that accurately target them towards their intended locations. This advancement enables more efficient delivery and has the potential to reduce unintended side effects in future AAV gene therapies.
For media inquiries, please contact:
Dr. Vibha Tamboli
Corporate Development Lead
